[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"menu":3,"$fzzpxJTeipXRfC064ik0Tim3TO8JRSOquCcOiDx_FvQM":210},{"main":4,"mainTranslated":17,"footer":45,"footerTranslated":109},[5,8,11,14],{"title":6,"url":7},"Course library","https:\u002F\u002Fwww.medmastery.com\u002Fcourse-library",{"title":9,"url":10},"Pricing","https:\u002F\u002Fwww.medmastery.com\u002Fpricing",{"title":12,"url":13},"Earn credits","https:\u002F\u002Fwww.medmastery.com\u002Fcme-credits",{"title":15,"url":16},"Institutions","https:\u002F\u002Fwww.medmastery.com\u002Finstitutions",{"de":18,"es":27,"fr":36},[19,21,23,25],{"title":20,"url":7},"Kurse",{"title":22,"url":10},"Preise",{"title":24,"url":13},"CME-Punkte",{"title":26,"url":16},"Organisationen",[28,30,32,34],{"title":29,"url":7},"Biblioteca de cursos",{"title":31,"url":10},"Precios",{"title":33,"url":13},"Gana créditos",{"title":35,"url":16},"Instituciones",[37,39,41,43],{"title":38,"url":7},"Cours",{"title":40,"url":10},"Tarifs",{"title":42,"url":13},"Obtenir des crédits",{"title":44,"url":16},"Établissements",[46,59,79,97],{"title":47,"group":48,"menu":49},"Company",true,[50,53,56],{"title":51,"url":52},"Our teachers","https:\u002F\u002Fwww.medmastery.com\u002Fteachers",{"title":54,"url":55},"About us","https:\u002F\u002Fwww.medmastery.com\u002Fabout-us",{"title":57,"url":58},"Work with us","https:\u002F\u002Fwww.medmastery.com\u002Fwork-with-us",{"title":60,"group":48,"menu":61},"Product",[62,64,67,70,73,76,78],{"title":63,"url":7},"Courses",{"title":65,"url":66},"Magazine","https:\u002F\u002Fwww.medmastery.com\u002Fmagazine",{"title":68,"url":69},"Podcast","https:\u002F\u002Fwww.medmastery.com\u002Fpodcasts",{"title":71,"url":72},"Webinars","https:\u002F\u002Fwww.medmastery.com\u002Fwebinars",{"title":74,"url":75},"Guides","https:\u002F\u002Fwww.medmastery.com\u002Fguides",{"title":15,"url":77},"https:\u002F\u002Fwww.medmastery.com\u002Finstitutions\u002F",{"title":9,"url":10},{"title":80,"group":48,"menu":81},"Legal",[82,85,88,91,94],{"title":83,"url":84},"Imprint","https:\u002F\u002Fwww.medmastery.com\u002Fimprint",{"title":86,"url":87},"Newsletter policy","https:\u002F\u002Fwww.medmastery.com\u002Fnewsletter-privacy-policy",{"title":89,"url":90},"Privacy policy","https:\u002F\u002Fwww.medmastery.com\u002Fprivacy-policy",{"title":92,"url":93},"Cookie Policy","https:\u002F\u002Fwww.medmastery.com\u002Fcookie-policy",{"title":95,"url":96},"Terms","https:\u002F\u002Fwww.medmastery.com\u002Fterms",{"title":98,"group":48,"menu":99},"Customer support",[100,103,106],{"title":101,"url":102},"FAQs","https:\u002F\u002Fwww.medmastery.com\u002Ffaqs",{"title":104,"url":105},"Contact","https:\u002F\u002Fwww.medmastery.com\u002Fcontact",{"title":107,"url":108},"support@medmastery.com","mailto:support@medmastery.com",{"de":110,"es":143,"fr":177},[111,118,128,137],{"title":112,"group":48,"menu":113},"Unternehmen",[114,116,117],{"title":115,"url":52},"Unsere Dozentinnen und Dozenten",{"title":54,"url":55},{"title":57,"url":58},{"title":119,"group":48,"menu":120},"Produkt",[121,122,123,124,125,126,127],{"title":20,"url":7},{"title":65,"url":66},{"title":68,"url":69},{"title":71,"url":72},{"title":74,"url":75},{"title":26,"url":77},{"title":22,"url":10},{"title":129,"group":48,"menu":130},"Rechtliches",[131,133,134,135,136],{"title":132,"url":84},"Impressum",{"title":86,"url":87},{"title":89,"url":90},{"title":92,"url":93},{"title":95,"url":96},{"title":138,"group":48,"menu":139},"Kundenservice",[140,141,142],{"title":101,"url":102},{"title":104,"url":105},{"title":107,"url":108},[144,151,162,171],{"title":145,"group":48,"menu":146},"Empresa",[147,149,150],{"title":148,"url":52},"Nuestros profesores",{"title":54,"url":55},{"title":57,"url":58},{"title":152,"group":48,"menu":153},"Producto",[154,156,157,158,159,160,161],{"title":155,"url":7},"Cursos",{"title":65,"url":66},{"title":68,"url":69},{"title":71,"url":72},{"title":74,"url":75},{"title":35,"url":77},{"title":31,"url":10},{"title":163,"group":48,"menu":164},"Información legal",[165,167,168,169,170],{"title":166,"url":84},"Aviso legal",{"title":86,"url":87},{"title":89,"url":90},{"title":92,"url":93},{"title":95,"url":96},{"title":172,"group":48,"menu":173},"Atención al cliente",[174,175,176],{"title":101,"url":102},{"title":104,"url":105},{"title":107,"url":108},[178,185,196,204],{"title":179,"group":48,"menu":180},"Entreprise",[181,183,184],{"title":182,"url":52},"Nos enseignants",{"title":54,"url":55},{"title":57,"url":58},{"title":186,"group":48,"menu":187},"Produit",[188,189,190,191,192,193,194],{"title":38,"url":7},{"title":65,"url":66},{"title":68,"url":69},{"title":71,"url":72},{"title":74,"url":75},{"title":15,"url":77},{"title":195,"url":10},"Tarification",{"title":197,"group":48,"menu":198},"Mentions légales",[199,200,201,202,203],{"title":197,"url":84},{"title":86,"url":87},{"title":89,"url":90},{"title":92,"url":93},{"title":95,"url":96},{"title":205,"group":48,"menu":206},"Service client",[207,208,209],{"title":101,"url":102},{"title":104,"url":105},{"title":107,"url":108},{"content":211,"related":294,"meta":366,"internal":378},{"title":212,"leadIn":213,"category":214,"elements":217,"becomeAnExpert":247,"author":284,"readDuration":292,"readDurationFormatted":293},"Incretin therapies in type 2 diabetes: clinical considerations for prescribing GLP-1 agonists","Incretin therapies play an expanding role in type 2 diabetes management. GLP-1–based treatments can improve glucose control, support weight loss, and provide important cardiometabolic benefits.",{"id":215,"name":216},1,"Course previews",[218,229,234,242],{"type":219,"data":220},"video",{"readDurationInSeconds":221,"video":222},365,{"platform":223,"name":224,"url":225,"size":226},"YouTube","GLP-1 Receptor Agonists | Incretin Therapies for Type 2 Diabetes | Management of Diabetes Mellitus","https:\u002F\u002Fyoutu.be\u002FHWmeWwBlJ0U",{"width":227,"height":228},200,113,{"type":230,"data":231},"free_text",{"readDurationInSeconds":232,"text":233},31.2,"\u003Cp dir=\"ltr\">\u003Cspan>Incretin therapies target a key physiologic response involved in post-meal glucose control. Normally, when glucose is given orally, it triggers a greater insulin release than when the same amount of glucose is given by IV.\u003C\u002Fspan>\u003Cstrong> \u003C\u002Fstrong>\u003Cspan>This response, called the incretin effect, is reduced in type 2 diabetes. By mimicking the action of natural GLP-1, these therapies enhance insulin release in response to food and help lower blood sugar levels effectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>In this lesson from our Advanced Management Strategies in Type 2 Diabetes course, you’ll learn how incretin therapies:\u003C\u002Fspan>\u003C\u002Fp>\u003Cul>\u003Cli dir=\"ltr\">\u003Cspan>Enhance insulin release in response to food\u003C\u002Fspan>\u003C\u002Fli>\u003Cli dir=\"ltr\">\u003Cspan>Slow gastric emptying\u003C\u002Fspan>\u003C\u002Fli>\u003Cli dir=\"ltr\">\u003Cspan>Improve overall blood sugar control\u003C\u002Fspan>\u003C\u002Fli>\u003Cli dir=\"ltr\">\u003Cspan>Support weight loss\u003C\u002Fspan>\u003C\u002Fli>\u003Cli dir=\"ltr\">\u003Cspan>Provide very high efficacy in lowering blood sugars, with a low risk of hypoglycemia\u003C\u002Fspan>\u003C\u002Fli>\u003C\u002Ful>\u003Cp dir=\"ltr\">\u003Cspan>Whether you’re starting therapy or revisiting treatment decisions, this lesson provides a clear, clinically grounded view of how incretin therapies are used in the advanced management of type 2 diabetes.\u003C\u002Fspan>\u003C\u002Fp>",{"type":235,"data":236},"cta",{"readDurationInSeconds":237,"text":238,"buttonText":239,"buttonUrl":240,"teachIllustration":241},4.266666666666667,"Start the first chapter of our Advanced Management Strategies in Type 2 Diabetes course for free","Start chapter 1 now","https:\u002F\u002Fwww.medmastery.com\u002Fuser\u002Fregister?target=%2Fcourses%2Fadvanced-management-strategies-in-type-2-diabetes","https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002Fa036f0ba-8d16-4e60-a026-921c26a71ce0",{"type":230,"data":243},{"readDurationInSeconds":244,"title":245,"text":246},183.73333333333335,"Transcript","\u003Ch3>\u003Cspan>The incretin effect in type 2 diabetes\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp dir=\"ltr\">[00:03]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>GLP-1 receptor agonists are a category of medications known as the incretins. Normally, when glucose is given orally, it triggers a greater insulin release than when the same amount of glucose is given IV. This phenomenon, called the incretin effect, highlights the role of glucose-sensitive receptors in the gastrointestinal tract. These receptors stimulate the release of hormones such as glucagon-like peptide, also known as GLP-1. \u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan>How incretin-based therapies work\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp dir=\"ltr\">[00:32]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>Unfortunately, in type 2 diabetes, the incretin effect is diminished. By mimicking the action of natural GLP-1, the GLP-1 agonists enhance insulin release in response to food, helping lower blood sugar levels effectively. GLP-1 is released by cells in the small intestine after a meal. Once in circulation, it travels to the pancreas and stimulates insulin secretion while also suppressing glucagon release. It slows gastric emptying, which increases satiety and helps patients feel full sooner and eat less. This delay in digestion also slows the post-meal rise in blood sugar. Together, these effects improve blood sugar control and support weight loss. For patients with type 2 diabetes, where the natural GLP-1 response is reduced, GLP-1 receptor agonists provide a valuable way to restore these benefits.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan>Dual incretin therapy: GLP-1 and GIP combinations\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp dir=\"ltr\">[01:31]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>A newer addition to this class combines GLP-1 receptor agonists with another hormone called gastric inhibitory polypeptide, or GIP. GIP works similarly to GLP-1 by enhancing insulin release in response to food. This combination, found in the medication tirzepatide, offers impressive efficacy for lowering blood sugar, enhancing satiety, and promoting weight loss. Unlike traditional GLP-1 receptor agonists, GIP does not slow gastric emptying, which may help reduce some of the gastrointestinal side effects commonly associated with this class of medications.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan>Additional benefits of incretin therapies\u003C\u002Fspan>\u003C\u002Fh3>\u003Ch4>\u003Cspan>Cardiovascular effects of incretin therapies\u003C\u002Fspan>\u003C\u002Fh4>\u003Cp dir=\"ltr\">[02:13]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>Beyond their role in lowering blood sugars, several GLP-1 receptor agonists have cardiovascular benefits and should be the initial treatment options for patients with type 2 diabetes and established cardiovascular disease. While the combination GLP-1 \u002F GIP receptor agonists haven’t yet demonstrated similar benefits, they are considered safe from a cardiovascular outcomes perspective. \u003C\u002Fspan>\u003C\u002Fp>\u003Ch4>\u003Cspan>Renal outcomes with incretin therapies\u003C\u002Fspan>\u003C\u002Fh4>\u003Cp dir=\"ltr\">[02:38]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>Several GLP-1 receptor agonists have shown potential to slow the progression of diabetic kidney disease in patients with chronic kidney disease, offering an additional layer of protection. While they may help reduce the risk of worsening kidney function, they do not reverse existing damage. Emerging evidence also suggests that combination therapies like tirzepatide may help preserve kidney function compared to glargine, though long-term studies are still ongoing to confirm these benefits.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan>Glycemic control with incretin-based therapies\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp dir=\"ltr\">[03:11]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>The GLP-1 receptor agonists have very high efficacy in lowering blood sugars and are also a reasonable option for patients with type 2 diabetes without other complications to help lower A1c and achieve glucose control. On average, they can reduce A1c by about 1%, and the combination therapies can achieve reductions of up to 2%. Most of these medications are injectables, but they are convenient to use, with many available as once-weekly injections. This dosing schedule can help improve adherence, especially for patients who find daily medications challenging.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan>Safety considerations with incretin therapies\u003C\u002Fspan>\u003C\u002Fh3>\u003Ch4>\u003Cspan>Common side effects of incretin therapies\u003C\u002Fspan>\u003C\u002Fh4>\u003Cp dir=\"ltr\">[03:49]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>Like any treatment, GLP-1 receptor agonists have potential side effects. The most common is nausea, which occurs due to the slowing of gastric emptying. The severity of nausea varies widely. Some patients tolerate these medications well, while others may struggle, even at low doses. Gradual dose titration can help minimize this side effect. These medications are contraindicated in gastroparesis, as their effects on gastric emptying could worsen symptoms.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch4>\u003Cspan>Additional considerations: pancreatitis\u003C\u002Fspan>\u003C\u002Fh4>\u003Cp dir=\"ltr\">[04:20]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>There are other considerations as well. Pancreatitis has been reported in some patients using GLP-1 receptor agonists, though it’s unclear if the medications are the direct cause. If pancreatitis develops, it’s appropriate to stop the medication. \u003C\u002Fspan>\u003C\u002Fp>\u003Ch4>\u003Cspan>C-cell hyperplasia in preclinical studies\u003C\u002Fspan>\u003C\u002Fh4>\u003Cp dir=\"ltr\">[04:36]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>Preclinical animal studies showed an increase in C-cell hyperplasia, which could increase the risk of medullary thyroid cancer, a cancer of the C cells in the thyroid. It is unclear if this is relevant for humans. As a precaution, these medications are not recommended for individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia types 1 or 2. However, there is no increased risk for other types of thyroid cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan>Low hypoglycemia risk and weight benefits of incretin therapy\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp dir=\"ltr\">[05:09]\u003C\u002Fp>\u003Cp dir=\"ltr\">\u003Cspan>One major advantage of GLP-1 and GIP receptor agonists is their low risk of hypoglycemia. Since they only enhance insulin release when blood sugar levels are elevated, such as after a meal, they are a safe option for patients at risk of low blood sugar. Additionally, their weight loss benefits have led to their approval as a weight loss treatment, even for individuals without diabetes. For patients with type 2 diabetes who are also working on weight management, these medications can be particularly helpful.\u003C\u002Fspan>\u003C\u002Fp>",{"courses":248,"showAwardsBelow":48},[249,268],{"id":250,"isFreeCmeCourse":251,"title":252,"type":253,"specialization":254,"teachers":256,"cmeCredits":258,"teacherIllustration":241,"backgroundImage":259,"relativeUrl":260,"lastChanged":261,"created":262,"description":263,"relativeURL":260,"meta":264},14080,false,"Advanced Management Strategies in Type 2 Diabetes","course",[255],"Endocrinology",[257],"Tracy Tylee, MD",5,"https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002Fa036f0b0-b71c-4991-bbb1-11919ae5f44a","\u002Fcourses\u002Fadvanced-management-strategies-in-type-2-diabetes","1768319766","1761578299","\u003Cspan id=\"docs-internal-guid-7def5223-7fff-6e53-ae4d-a7da75f6cf40\">Confidently deliver advanced care for adults with type 2 diabetes. This course shows you how to select and sequence therapies, start and adjust insulin using glucose data, and build individualized plans that fit each patient’s goals and context. You will integrate lifestyle counseling, diabetes technology, and risk reduction strategies to improve glycemic control and long-term outcomes.\u003C\u002Fspan>",{"duration":265,"quizzes":266,"lessons":267},12036,9,43,{"id":269,"isFreeCmeCourse":251,"title":270,"type":253,"specialization":271,"teachers":272,"cmeCredits":273,"teacherIllustration":274,"backgroundImage":275,"relativeUrl":276,"lastChanged":277,"created":278,"description":279,"relativeURL":276,"meta":280},14079,"Diabetes Mellitus Essentials",[255],[257],5.5,"https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002F9fe1dd99-6a02-4702-9c27-0af1632a7380","https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002F9fe1de7d-ba19-4358-9a24-277934d51c18","\u002Fcourses\u002Fdiabetes-mellitus-essentials","1769265890","1757924606","Confidently manage diabetes from day one! This course gives you the fundamental skills to assess, treat, and monitor patients with diabetes safely and effectively. You’ll learn how to select appropriate therapies, start and adjust insulin regimens, and use blood glucose readings to guide dosing. The course also covers screening for complications, interpreting lab values, and applying strategies to prevent disease progression. By the end, you’ll be able to deliver patient-centered care that supports improved glycemic control and long-term health outcomes.",{"duration":281,"quizzes":282,"lessons":283},11342,11,50,{"id":285,"name":257,"image":286,"profession":287,"relativeUrl":290,"specializations":291},3748,"https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002F9c43cefc-88e6-4632-a711-cf90c6d98c24",{"name":288,"description":289},"Endocrinologist","Tracy is an Associate Professor of Endocrinology at the University of Washington, and Program Director for the Endocrinology Fellowship Program.","\u002Fteachers\u002Ftracy-tylee-md",[255],228,"4m",[295,323,342],{"id":296,"title":297,"text":298,"image":299,"author":307,"path":316,"readDuration":317,"readDurationFormatted":318,"internal":319},1350,"How to Recognize INOCA (ANOCA) on an Exercise Stress Test ","Angina, abnormal stress test, clean coronaries—that's INOCA (or ANOCA), and it carries real risk. Learn to recognize and report it with exercise stress ECG.",{"alt":300,"title":301,"size":302,"location":304},"Illustration of the heart's coronary vasculature showing large coronary arteries and the extensive network of smaller vessels affected in INOCA (ischemia with nonobstructive coronary arteries).","",{"width":303,"height":303},1200,{"bucket":305,"key":306},"public-drupal-medmastery-assets-production","\u002F2026-05\u002FC17(1)_magazine image_0.png",{"id":308,"title":309,"relativeURL":310,"image":311,"professionLong":312,"profession":313,"weight":315},1563,"Franz Wiesbauer, MD MPH","\u002Fteachers\u002Ffranz-wiesbauer-md-mph","https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002F9c43cef0-41ee-4005-9e4a-d8711c816401","Franz is the founder and CEO of Medmastery. He is an internist with a specialization in cardiology and a master’s in public health from Johns Hopkins University.",{"name":314},"Internist",4,"\u002Fmagazine\u002Fexercise-stress-ecg-inoca",141,"3m",{"created":320,"updated":321,"published":322},1778115738,1778118425,1778118255,{"id":324,"title":325,"text":326,"image":327,"author":333,"path":335,"readDuration":336,"readDurationFormatted":337,"internal":338},1348,"Hyperlipidemia screening: who, when, & what to measure","Testing for hyperlipidemia can help you mitigate your patients' cardiovascular risk. Learn who to screen and when, which measures to request, and how to stratify risk.",{"alt":328,"title":301,"size":329,"location":331},"Lipid panel blood sample tubes used to test for hyperlipidemia in a laboratory setting",{"width":330,"height":330},600,{"bucket":305,"key":332},"\u002F2026-04\u002FC121_magazine image.png",{"id":308,"title":309,"relativeURL":310,"image":311,"professionLong":312,"profession":334,"weight":315},{"name":314},"\u002Fmagazine\u002Ftest-for-hyperlipidemia",246,"5m",{"created":339,"updated":340,"published":341},1777403036,1777572381,1777412421,{"id":343,"title":344,"text":345,"image":346,"author":351,"path":360,"readDuration":361,"readDurationFormatted":293,"internal":362},1347,"Outpatient care for COPD exacerbations","Most acute COPD exacerbations can be managed with outpatient treatment. Learn how to treat mild and moderate COPD exacerbations—and when to escalate care.",{"alt":347,"title":301,"size":348,"location":349},"Older patient using a handheld nebulizer to inhale bronchodilator medication during an acute COPD exacerbation",{"width":330,"height":330},{"bucket":305,"key":350},"\u002F2026-04\u002FC133(4)_ exacerbations_magazine image.png",{"id":352,"title":353,"relativeURL":354,"image":355,"professionLong":356,"profession":357,"weight":359},5365,"Siamak Moayedi, MD","\u002Fteachers\u002Fsiamak-moayedi-md","https:\u002F\u002Fmedmastery-backend-prod-kjbeds.s3.eu-west-1.amazonaws.com\u002Fmedia\u002Fimages\u002F9c43cf02-1064-4074-817b-0eb5de6ded74","Professor and Director of Medical Student Education, University of Maryland and Course Director, Essential and Critical Procedures, Emergency Medicine.",{"name":358},"Emergency medicine physician",1533,"\u002Fmagazine\u002Facute-copd-exacerbation-treatment",191,{"created":363,"updated":364,"published":365},1776705362,1776710540,1776710541,{"seo":367,"og":370},{"title":368,"description":369},"Incretin therapies for type 2 diabetes: GLP-1 insights | Medmastery","Understand how incretin therapies work in type 2 diabetes, including the clinical role of GLP-1 receptor agonists and key considerations for their use.",{"title":368,"description":371,"image":372},"Understand how incretin therapies work in type 2 diabetes. Learn the clinical role of GLP-1 receptor agonists and key considerations for their use.",{"alt":373,"title":301,"size":374,"location":376},"Three injectable medication pens used in incretin therapies for diabetes management, one pen shown with the outer cap removed.",{"width":375,"height":375},1201,{"bucket":305,"key":377},"\u002F2025-12\u002Fincretin-therapy-pens.png",{"id":379,"created":380,"updated":381,"published":380},1334,1765949243,1767919922]